Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Malignant lymphoma presenting with an elevated serum CA-125 level

R L Apel1, B J Fernandes

  • 1Department of Pathology, Mount Sinai Hospital, Toronto, Ontario, Canada.

Archives of Pathology & Laboratory Medicine
|April 1, 1995
PubMed
Summary

Elevated CA-125 levels in lymphoma patients may stem from reactive mesothelial cells, not tumor cells. This finding broadens the clinical use of CA-125 beyond ovarian cancer monitoring.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diffuse Large-Cell Lymphoma in the Elderly: Does a Clinically Indolent Subset Exist?

Leukemia & lymphoma·2016
Same author

Maternal ABO-mismatched blood for intrauterine transfusion of severe hemolytic disease of the newborn due to anti-Rh17.

Transfusion·2004
Same author

Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.

Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics·2001
Same author

Insecure attachment in a subgroup with ulcerative colitis defined by ANCA status.

Digestive diseases and sciences·2001
Same author

Novel beta-thalassemia mutation in patients of Jewish descent: [beta 30(B12)Arg-->Gly or IVS-I(-2)(A-->G)].

Hemoglobin·1998
Same author

Novel beta 0-thalassemia mutation in a Canadian woman of British descent (codons 72/73, -AGTGA, +T).

Hemoglobin·1997

Area of Science:

  • Oncology
  • Immunohistochemistry
  • Biomarker Research

Background:

  • Cancer antigen 125 (CA-125) is a glycoprotein primarily associated with ovarian carcinoma monitoring.
  • Elevated serum CA-125 levels are rarely reported in patients with malignant lymphoma, with unclear pathophysiology.
  • Understanding the source of CA-125 in non-ovarian malignancies is crucial for accurate diagnosis and monitoring.

Observation:

  • An elderly female patient with lymphoma presented with constitutional symptoms and markedly elevated serum CA-125.
  • Post-mortem examination revealed widespread lymphoma with peritoneal involvement.
  • Immunohistochemistry showed CA-125 expression in reactive mesothelial cells, but not in lymphoma cells.

Findings:

  • The study supports the hypothesis that elevated CA-125 in lymphoma patients originates from reactive mesothelial cells in the peritoneum.
  • CA-125 production by mesothelium can occur in various peritoneal diseases, both benign and malignant.
  • Lymphoma cells themselves did not exhibit CA-125 immunoreactivity.

Implications:

  • The clinical utility of CA-125 may extend beyond ovarian cancer, potentially serving as a marker in other peritoneal diseases.
  • This research clarifies a previously misunderstood phenomenon in lymphoma patients with elevated CA-125.
  • Further investigation into mesothelial cell involvement in biomarker production is warranted for broader diagnostic applications.

Related Experiment Videos